<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00088608</url>
  </required_header>
  <id_info>
    <org_study_id>CSOM230B2208</org_study_id>
    <nct_id>NCT00088608</nct_id>
  </id_info>
  <brief_title>A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease</brief_title>
  <official_title>A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 Âµg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The study treatment period is 15 days in length and includes patients with pituitary
      Cushing's disease who are candidates for surgical intervention as well as and patients who
      have recurrent Cushing's post operatively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Free Cortisol after 15 days of treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum cortisol</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACTH</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical manifestations</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of biomarkers</measure>
  </secondary_outcome>
  <enrollment type="Actual">26</enrollment>
  <condition>Cushing's Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOM230 s.c.</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pituitary Cushing's disease within the two months prior to study entry

          -  Patients for whom written informed consent to participate in the study has been
             obtained

          -  Female patients of child bearing potential who have not undergone clinically
             documented total hysterectomy and/or ovariectomy, or tubal ligation must agree to use
             barrier contraception throughout the course of the study, and for one month after the
             study has ended

        Exclusion Criteria:

          -  Female patients who are pregnant or lactating

          -  Patients who have been previously treated with certain medications may be required to
             be without certain medications prior to entering the study

          -  Poorly controlled diabetes mellitus as indicated by the presence of ketoacidosis or
             HgbA1C &gt; 10

          -  Patients who have congestive heart failure, unstable angina, cardiac arrhythmia or
             history of acute MI less than one year prior to the study entry or clinically
             significant impairment in cardiovascular function (e.g. blood pressure of 190/100mmHg
             or greater)

          -  Patients with chronic liver disease

          -  Patients with clotting disorders or abnormal blood counts

          -  History of immuno-compromise, including a positive HIV test result

          -  Patients with active gall bladder disease

          -  Patients who have participated in any clinical investigation with an investigational
             drug within 1 month prior to dosing

          -  Patients with active malignant disease (with the exception of basal cell carcinoma or
             carcinoma in situ of the cervix)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Pituitary Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital NE Unit</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Endocrinology Associates</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2443</url>
    <description>Novartis Clinical Trial Results on CSOM230B2208</description>
  </link>
  <results_reference>
    <citation>Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009 Jan;94(1):115-22. doi: 10.1210/jc.2008-1008. Epub 2008 Oct 28.</citation>
    <PMID>18957506</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2004</study_first_submitted>
  <study_first_submitted_qc>July 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2004</study_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cushing Syndrome</mesh_term>
    <mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
    <mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pasireotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

